Contineum Therapeutics (CTNM) Total Liabilities (2023 - 2026)

Contineum Therapeutics' Total Liabilities history runs 4 years deep, the most recent figure standing at $11.3 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 16.21% year-over-year to $11.3 million in Q1 2026; TTM through Mar 2026 was $11.3 million, a 16.21% decrease from a year earlier, with the FY2025 full-year figure at $15.7 million, up 5.9% from the prior year.
• Total Liabilities fell to $11.3 million in Q1 2026 per CTNM's latest filing, from $15.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $15.7 million in Q4 2025 and bottomed at $3.9 million in Q2 2024.
• The 4-year median for Total Liabilities is $10.8 million (2025), against an average of $9.9 million.
• Across the five-year window, Total Liabilities soared 198.49% in 2025 and fell 16.21% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $5.7 million in 2023, then surged by 159.22% to $14.8 million in 2024, then grew by 5.9% to $15.7 million in 2025, then slipped by 27.76% to $11.3 million in 2026.
• Per Business Quant, the three latest CTNM Total Liabilities figures stand at $11.3 million (Q1 2026), $15.7 million (Q4 2025), and $10.4 million (Q3 2025).